<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C187DCF6-A1D6-47D7-ABEF-F9B4980DB5A4"><gtr:id>C187DCF6-A1D6-47D7-ABEF-F9B4980DB5A4</gtr:id><gtr:name>Sarepta Therapeutics Inc.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Child Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C187DCF6-A1D6-47D7-ABEF-F9B4980DB5A4"><gtr:id>C187DCF6-A1D6-47D7-ABEF-F9B4980DB5A4</gtr:id><gtr:name>Sarepta Therapeutics Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/483D5886-D9B1-46DB-87FB-A90770EBBAA1"><gtr:id>483D5886-D9B1-46DB-87FB-A90770EBBAA1</gtr:id><gtr:firstName>Francesco</gtr:firstName><gtr:surname>Muntoni</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E24F901-A38D-4793-9437-35EE3F8CC361"><gtr:id>6E24F901-A38D-4793-9437-35EE3F8CC361</gtr:id><gtr:firstName>Dominic</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wells</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65EB5007-A4FD-493B-8EA3-3B18BA240012"><gtr:id>65EB5007-A4FD-493B-8EA3-3B18BA240012</gtr:id><gtr:firstName>Jennifer</gtr:firstName><gtr:otherNames>E</gtr:otherNames><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/95DF1C05-09A0-412A-87F2-6D0A6175BFD7"><gtr:id>95DF1C05-09A0-412A-87F2-6D0A6175BFD7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Wood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE75F14C-8BF0-4A29-8B82-81205C517C27"><gtr:id>FE75F14C-8BF0-4A29-8B82-81205C517C27</gtr:id><gtr:firstName>John George</gtr:firstName><gtr:surname>Dickson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/12776B47-8A7E-42A7-89AF-B9DDF6A4E701"><gtr:id>12776B47-8A7E-42A7-89AF-B9DDF6A4E701</gtr:id><gtr:firstName>Voker</gtr:firstName><gtr:surname>Straub</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/49FD76CE-51D7-4DD9-8F96-D58F198F0DCA"><gtr:id>49FD76CE-51D7-4DD9-8F96-D58F198F0DCA</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>Ross</gtr:otherNames><gtr:surname>Graham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6A4534BA-ABC4-43A8-8811-4D6064526CBB"><gtr:id>6A4534BA-ABC4-43A8-8811-4D6064526CBB</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:surname>Bushby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502130"><gtr:id>99027E1A-7088-4292-909F-A5607F1A8AF8</gtr:id><gtr:title>A phase I/II clinical trial in Duchenne muscular dystrophy using systemically delivered antisense oligonucleotides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502130</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Duchenne muscular dystrophy (DMD), a fatal muscle degenerative disorder, arises from mutations in the dystrophin gene. Antisense oligonucleotide (AO) therapy has the potential to restore effectively the production of dystrophin, the defective protein, in 60% of DMD. This could result in increased life expectancy through improved muscle survival and function. Members of this Consortium have demonstrated the potential of this technique to skip mutated dystrophin exons, restore the reading frame and generate functional dystrophin protein. After having demonstrated proof-of-principle in human cell culture and animal model studies, we are currently involved in a Department of Health funded phase I/II trial aimed at assessing safety and efficacy of acutely administered AOs in DMD boys with deletions that can be rescued by skipping dystrophin exon 51. 

The aim of the current proposal is to perform a repeated administration, systemic (IV) delivery phase I/II trial in 2 groups of individuals with DMD and different deletions, in whom dystrophin restoration could be achieved by using 2 different AOs. Indeed recent animal work indicates that repeated administration of IV AO is associated with the significant restoration of dystrophin expression in most muscles. In parallel, further laboratory studies will be focused on developing AO which could potentially restore dystrophin expression in most DMD mutations; and perfection methods of systemic delivery so that lower dosage of AO could be used. 
This Consortium, reporting to a Scientific Board, will ensure directed progress and enable scientists to adapt research where necessary to achieve the desired goal of effective genetic therapy for individuals affected by DMD.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1176400</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sarepta Therapeutics Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>study of AVI-4658 to induce dystrophin expression in DMD patients</gtr:description><gtr:id>1EC0385B-AC22-46D8-A72F-FD82AEE97BF8</gtr:id><gtr:impact>An intramuscular phasel/ll clinical trial in seven DMD boys from October 2007-March 2009. PubMed ID 19713152
A systemic phasel/ll clinical trial in 19 DMD boys in two centres in the UK from January 2009-April 2010. PubMed ID 21784508</gtr:impact><gtr:outcomeId>D2B03147BF5-1</gtr:outcomeId><gtr:partnerContribution>AVI, now Sarepta, provided clinical grade study drug</gtr:partnerContribution><gtr:piContribution>Since 2005 Muntoni is the PI of the multidisciplinary MDEX Consortium to promote collaborative translation research for Duchenne muscular dystrophy (www.mdex.org.uk). This consortium has already deleivered two experimental therapies using antisense oligonucleotides (Kinali etal, Lancet neurology 2009; Cirak et al, Lancet 2011). In 2011 additional funds from the AFM (French Association for Myopathies) allowed the MDEX consortiumto extend its range of collaboration to France with groups in Paris and Montpellier (now International MDEX). Recently (2011) the MDEX Consortium has also received funding from the Wellcome Trust of Health for preclinical optimisation and assessment of the safety and efficacy of a new generation of antisense oligonucleotides in Duchenne muscular dystrophy.
In 2008 Muntoni contributed, with his move from Imperial College to UCL, to the application to MRC for a translation research centre in neuromuscular diseases (Hanna-PI, Muntoni-deputy director) which links London and newcastle. The centre has been highly successful and metrics of success are available on the MRC Centre MRC webpages.
Between 2007 and 2011, Muntoni has been one of the PIs of the EU funded TREAT-NMD network of excellence, and resonsible for the translation research aspects of duchenne muscular dystrophy. Muntoni is currently involved in 2 additional EU funded initiatives as a co-PI.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>parent organisation meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4AFB1ED0-B0C3-40B9-BF2E-42631EA5CD1A</gtr:id><gtr:impact>presentations by various scientists and laypersons associated with DMD

attendance of experts in the field of DMD</gtr:impact><gtr:outcomeId>E53ABBA52EB</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination for Industrial partners</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>0A0E768F-C5B5-4F86-BF72-CF3E1ACF648A</gtr:id><gtr:impact>Information regarding disease course and therapeutic strategies

improved awareness from industrial partners</gtr:impact><gtr:outcomeId>98A8046C26B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDEX website (http://www.mdex.org.uk/)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>5228C4F8-9030-4253-BC74-FBFD5B78AC50</gtr:id><gtr:impact>website information and updates of MDEX Consortium activity http://www.mdex.org.uk/

request for information from interested parties</gtr:impact><gtr:outcomeId>BB023736C2D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EMEA - TREAT-NMD meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>AE24AAD4-5BF5-4F40-865F-23BD4F852236</gtr:id><gtr:impact>Meeting at EMEA organised by me (but hosted at EMEA) to discuss personalised medicine for DMD

workshop report to published
20347306 Muntoni F (May, 2010) The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009., Neuromuscular disorders : NMD 20, 5, 355-62</gtr:impact><gtr:outcomeId>A243806D1A8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination articles for advocacy groups magazines</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>AF214E87-D324-4E62-9699-56F0450ADC00</gtr:id><gtr:impact>Articles and interviews published in Action Duchenne and in Muscular Dystrophy Campaign UK Charities. The same for Muscular Dystrophy Association USA, and for MDA Australia, and for Association Francaise Myopathies.

Patient queries, request of more infromation/ clarification. Contact with industry</gtr:impact><gtr:outcomeId>318B8AD2EF0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>House of Parliament presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3B842EC5-D02F-4B34-8E73-2CF77C224FF5</gtr:id><gtr:impact>Presentation to the all parliament group workforce on muscular dystrophy

Improved awareness of politicians</gtr:impact><gtr:outcomeId>1B00B832744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIH/FDA conference on antisense oligonucleotide therapies in neuromuscular disease, Washington September 27-28, 2010</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>214A3960-F816-469A-90E8-661C7880E17C</gtr:id><gtr:impact>attended by representatives from FDA, NIH, industry, academics and parent organisation involved in Antisense Oligonucleotide Therapies in Neuromuscular Disorders

Presented concluding remark lecture on 'Lessons on Development of AON drugs for Neuromuscular Disease'.</gtr:impact><gtr:outcomeId>WRsdpipSwaG</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>409000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Translation Research Centre (ICH PI)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>502A3F59-C54F-4AB8-9FD8-1FE44F9F456C</gtr:id><gtr:outcomeId>nqZXJf7CUbD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2468621</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Advanced antisense oligonucleotide technology for exon skipping in Duchenne muscular dystrophy (co PI)</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0DC0A6C4-3F5F-4DF4-B2C1-F7E52040A5AE</gtr:id><gtr:outcomeId>aNA7LkNcERW0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant (PI)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>8D96F4B5-4B4D-49F3-B7CF-B61DD140A8C8</gtr:id><gtr:outcomeId>GCd1pVSPHyg0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11535</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Contribution towards research Therapist to support clinical trials (PI)</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F229EBAF-CBC7-422C-915F-A35ACFEFD40D</gtr:id><gtr:outcomeId>LqMkp7Yjqki0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant (co PI)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Muscular Dystrophy UK</gtr:fundingOrg><gtr:id>211BF672-AD26-4186-AFF2-EE04BAC2E406</gtr:id><gtr:outcomeId>H9vwcfiZvkT0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The antisense oligonucleotide developed and used by our consortium in Phase Ib/IIa studies as part of the MRC funded activity is undergoing further IIb study by the company AVI, now Sarepta</gtr:description><gtr:id>43447BC2-5462-47C1-8881-A0ABA6DAB9A6</gtr:id><gtr:impact>now in IIb studies</gtr:impact><gtr:outcomeId>ZgAvTWBbAEz</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Eteplirsen</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We correlated muscle MRI to histological findings in muscular dystrophy patients</gtr:description><gtr:id>33E66FBA-FF7E-4C73-9860-1AF81D316D9A</gtr:id><gtr:impact>peer review publication</gtr:impact><gtr:outcomeId>9E513F86EE1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>muscle MRI</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>to quantify the amount of positive dystrophin fibres in tissue</gtr:description><gtr:id>706831BE-287C-4E12-AD2B-31E3424ADD94</gtr:id><gtr:impact>assists in the efficacy outcome of the clinical trial.
Peer reivewed publications.</gtr:impact><gtr:outcomeId>E08D6AB80E7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>IHC quantitation</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DMD patients biological material (primary cell cultures)</gtr:description><gtr:id>DABB6812-5587-4B89-892C-7AFF8CB8A980</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>D7277EACADA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>DMD patients</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BAB3E12A-914A-42A3-A17A-8A937190EAFC</gtr:id><gtr:title>Emotional impact of genetic trials in progressive paediatric disorders: a dose-ranging exon-skipping trial in Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>Child: care, health and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25aec2e2ccedc799abc36f4ac2f05229"><gtr:id>25aec2e2ccedc799abc36f4ac2f05229</gtr:id><gtr:otherNames>Garralda ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1862</gtr:issn><gtr:outcomeId>pm_14395_25_22676208</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3B1FFD-424F-4159-93A0-BB2898C5CCF8</gtr:id><gtr:title>Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4345298aa80f7aab384e189cb31b897"><gtr:id>f4345298aa80f7aab384e189cb31b897</gtr:id><gtr:otherNames>Kinali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>2E9A3FC97BC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66733686-68BE-43E2-AEA4-56740EEC7AC5</gtr:id><gtr:title>Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b543b06313b787c174fd8fee9da7b7f5"><gtr:id>b543b06313b787c174fd8fee9da7b7f5</gtr:id><gtr:otherNames>Arechavala-Gomeza V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>rRch9qYQEMQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90532075-407E-413B-B076-F054C350CA26</gtr:id><gtr:title>Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/baf93ecbab15b08ce52d70b1af9453dc"><gtr:id>baf93ecbab15b08ce52d70b1af9453dc</gtr:id><gtr:otherNames>Cirak S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>DUiPcNmuWVF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A09729EF-6BE6-4CB6-8DEB-AB2F9B042F21</gtr:id><gtr:title>A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58cdb4a8130aa13e41ef654e326a54cd"><gtr:id>58cdb4a8130aa13e41ef654e326a54cd</gtr:id><gtr:otherNames>Walmsley GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55faa1aa1916f454</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FFCD683-F99A-4C91-8E9D-52976715386E</gtr:id><gtr:title>Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b222eb2887308b18e862b45fbb62c88b"><gtr:id>b222eb2887308b18e862b45fbb62c88b</gtr:id><gtr:otherNames>Geranmayeh F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>fRDJhgiRhje</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832E15B2-AE4B-46C0-B7F5-1D16D559DA6D</gtr:id><gtr:title>Correspondence: Measuring dystrophin-faster is not necessarily better.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b543b06313b787c174fd8fee9da7b7f5"><gtr:id>b543b06313b787c174fd8fee9da7b7f5</gtr:id><gtr:otherNames>Arechavala-Gomeza V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>pm_14395_25_22777248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAF5C94C-E32B-4346-9821-C17075BB384B</gtr:id><gtr:title>Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.</gtr:title><gtr:parentPublicationTitle>Human gene therapy methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7048e1621ef557498f13646f8b99fb"><gtr:id>5e7048e1621ef557498f13646f8b99fb</gtr:id><gtr:otherNames>Anthony K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6536</gtr:issn><gtr:outcomeId>pm_14395_25_23075107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93C335F4-9CB2-4819-8025-B71871097EC1</gtr:id><gtr:title>MLC1 is associated with the dystrophin-glycoprotein complex at astrocytic endfeet.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7180bbadbd51cbaa8dbb02a1acddcfa9"><gtr:id>7180bbadbd51cbaa8dbb02a1acddcfa9</gtr:id><gtr:otherNames>Boor I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>ZSnz8PNiEMu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>243F902C-028A-47D4-AF49-55BE69AB3974</gtr:id><gtr:title>Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f4c7719ed465cd75d51221c8bde3870"><gtr:id>6f4c7719ed465cd75d51221c8bde3870</gtr:id><gtr:otherNames>Cazzella V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_14395_25_22968481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8EB8E8C-3C9D-4CF6-AF59-2A0BFAB489D0</gtr:id><gtr:title>Psychosocial adjustment in siblings of young people with Duchenne muscular dystrophy.</gtr:title><gtr:parentPublicationTitle>European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f40c1d1c4009ad9d9e5fceff1d9ec2f1"><gtr:id>f40c1d1c4009ad9d9e5fceff1d9ec2f1</gtr:id><gtr:otherNames>Read J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1090-3798</gtr:issn><gtr:outcomeId>cauw6Uduwz7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EC5400C-B472-4820-8B34-0CB7D3B594AD</gtr:id><gtr:title>194th ENMC international workshop. 3rd ENMC workshop on exon skipping: towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8-10 December 2012, Naarden, The Netherlands.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f0682b259759dcbf352bf526183086e"><gtr:id>3f0682b259759dcbf352bf526183086e</gtr:id><gtr:otherNames>Aartsma-Rus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>pm_14395_25_23890933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD789CD-EE82-42CA-B01C-AE3B0556091B</gtr:id><gtr:title>Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b543b06313b787c174fd8fee9da7b7f5"><gtr:id>b543b06313b787c174fd8fee9da7b7f5</gtr:id><gtr:otherNames>Arechavala-Gomeza V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn><gtr:outcomeId>pm_14395_25_22533380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05E545FE-FD84-419F-946C-E1AE64C12BCC</gtr:id><gtr:title>Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/37d06c45219146e15e2d45a706037126"><gtr:id>37d06c45219146e15e2d45a706037126</gtr:id><gtr:otherNames>Popplewell LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>hyxazMzsgsN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F92EE0B-3D66-4154-8856-5C2FA6C432B6</gtr:id><gtr:title>Targeting RNA to treat neuromuscular disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d12a81c1a41c39038e9286100f8688e7"><gtr:id>d12a81c1a41c39038e9286100f8688e7</gtr:id><gtr:otherNames>Muntoni F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_14395_25_21804598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BE03FD4-A5B5-44DA-95BF-5730E44ABACA</gtr:id><gtr:title>The contribution of human synovial stem cells to skeletal muscle regeneration.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e84e3707839d90302345838b73f672b7"><gtr:id>e84e3707839d90302345838b73f672b7</gtr:id><gtr:otherNames>Meng J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>TPVuyEM3ZtY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D3B778D-63B7-45BE-9A7F-D2769F68E457</gtr:id><gtr:title>Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations.</gtr:title><gtr:parentPublicationTitle>Neuromuscular disorders : NMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdd956acf2cbdc15ced38e5429a2f68c"><gtr:id>fdd956acf2cbdc15ced38e5429a2f68c</gtr:id><gtr:otherNames>Forrest S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0960-8966</gtr:issn><gtr:outcomeId>gkNFfMG1v2F</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502130</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>